Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

  • ALL984
  • 0 Pages
  • July 2014
  • Pharmaceuticals

Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Global biosimilars/follow-on-biologics market accounted for $1,358 million in 2013 and it is anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from 2014 to 2020.

Regulations for biosimilars plays a vital role in maintaining the viability and balance between original and biosimilar products. Various regulatory authorities, namely EMA and the U.S. FDA are actively regulating the biosimilars market. Regulations in the European union are considered benchmark around the world, as the guidelines proposed are most stringent for validation and commercialization of biosimilars. High profitability is the attractive aspect that is enticing companies to invest in the biosimilars industry. 

Geographically, Biosimilars market is segmented into North America, Europe, Asia-Pacific and LAMEA. Due to favorable regulatory policies designed by the European Medical Association, the European market has been maximizing on the biosimilars market. Asia-Pacific and LAMEA market would witness a substantial rise in the use of biosimilars, as the demand for cost effective treatment is growing due to the prevalence of chronic diseases. Collaboration with local players would be a key opportunity that could be fully explored by the biosimilars manufacturers in developing economies. Many companies such as Amgen and Novartis are collaborating with Asian players to gain a foothold in the biopharmaceutical market. 

Europe was the first region to draft guidelines for approval of biosimilars in 2006. Nevertheless, in 2008, the first biosimilars version of Granulocyte colony-stimulating factor (G-CSF) was introduced in the European Union under the regulatory guidance of European Medical Association (EMA). Currently, there are three biosimilar versions of G-CSF available in the European market, namely Ratiograstim/Tevagrastim/Biograstim, Zarzio/Filgrastim Hexal and Nivestim/Pliva/Mayne filgrastim. Adding to the G-CSF biosimilars, the insulin biosimilars also showcase tremendous potential in the future. 

Key Benefits

  • The study is segmented in a strategic divisions to gain deeper insights into the market dynamics and understand the competitive environment of the overall market 
  • Financial market forecast is provided for the next eight years by considering 2013 as the base year
  • Comprehensive and quantitative data about changing market trends, intensifying competition and opportunities in biosimilars market are provided to make better business decisions
  • Porter’s Five Forces model and SWOT analysis of the overall market is provided to help stakeholders gain strategic insights of the market
  • Deep dive analysis of key market players and strategies adopted by them are expounded to provide valuable information on the top contenders in the market
  • Identification of key investment pockets for the biosimilars market is strategically dealt to assist the stakeholders 

Key Deliverables

Global biosimilars/follow-on-biologics market is categorized into technology, product types, applications, services and geography.


  • Monoclonal Antibodies (MAb) Technology
  • Recombinant DNA Technology (rDNA technology)
  • Nuclear magnetic resonance (NMR) technology
  • Chromatography
  • Electrophoresis
  • Mass Spectrometry
  • Western Blotting
  • Bioassay


  • Recombinant Non-Glycosylated Protein
    • Human Growth Hormone
    • Insulin
    • Interferon
    • Granulocyte colony stimulating factor (G-CSF)
    • Others
  • Recombinant Glycosylated Protein
    • Erythropoietin
    • Monoclonal antibodies
    • Others
  • Peptides
    • Octreotide
    • Desmopressin
    • Cyclosporine
    • Calcitonin
    • Eptifibatide
    • LH-RH (Leuprolide)
    • Nesiritide
    • Teriparatide
    • Bivalirudin
    • Enfuvirtide
    • Glucagon


  • Blood disorders
    • Chemotherapy induce Anaemia
    • Hemophilia
    • Pulmonary embolism
  • Oncology diseases
    • Lungs cancer
    • Colorectal cancer
    • Breast cancer
    • Cervical cancer
    • Leukemia
    • Prostate cancer
  • Chronic and autoimmune diseases
    • Neutropenia
    • Multiple sclerosis
    • Cystic Fibrosis
    • Rheumatoid arthritis (RA)
    • Acromegaly
    • Leprosy
  • Growth hormone deficiencies
  • Others


  • Contract Research and Manufacturing Services (CRAMS)
  • Clinical Trials


  • North America
  • Europe
  • Asia-Pacific
Please Select Format

Enquiry About Report

Need More Information

Contact us
+ 1-800-910-6452
+91 20 66346066
--- or ---



Global General Medicine Education Publishing Market (Type, Geography) Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Opportunities, Segmentation, Forecast (2013-2020)

General medicine is a branch of medicine that deals with diagnosis and treatment of diseases associated with internal organs. It is also called as Internal Medicine. General medicine education market has shown substantial growth due to the adoption of internal medicine as a career option by medical students.

April 2018| $5370 | Pre Book Price:$4699

Cancer Vaccine Market Global Scenario, Market Size, Outlook, Trend and Forecast, 2015- 2024

Cancer vaccines are biological response modifiers. These vaccines work by stimulating or restoring the immune system�s ability to fight against infections and diseases. It is used either as stand-alone therapies ...

April 2018| $4995 | Pre Book Price:$4371

World Active Pharmaceutical Ingredient (API) Market - Opportunities and Forecasts, 2014 - 2020

Increase in Abbreviated New Drug Applications (ANDA) over the past years has fostered the demand for API market. Furthermore, Indian companies making increased entries related to Drug Master File (DMF) ...

April 2018| $5370 | Pre Book Price:$4699

Anterior Uveitis Asia-Pacific Market Research Report, 2014 - 2020

Anterior uveitis is an eye inflammation that involves middle layer of the eye specifically, iris (colored part of the eye) and ciliary body (adjacent tissue). Untreated anterior uveitis results in ...

April 2018| $2850 | Pre Book Price:$2494

Nanomedicine Asia-Pacific Market Research Report, 2014 - 2020

Nanomedicine is the applied branch of nanotechnology. Application of nanomedicines ranges from nonmaterial to nanoelectronic and in the near future, it could possibly expand to molecular nanotechnology. Biological, pharmaceutical and ...

April 2018| $2850 | Pre Book Price:$2494

Autoimmune Disorders Treatment Asia-Pacific Market Research Report, 2014 - 2020

Graves disease, Multiple sclerosis, Myasthenia gravis, Rheumatoid arthritis, Pernicious anemia and Systemic lupus erythematosus are the most prevalent types of autoimmune disorders. The prevalence of autoimmune diseases is high in ...

April 2018| $2850 | Pre Book Price:$2494

2018 © Copyright Big Market Research

View Pricing >>